MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jocn.2020.01.041

Медицинская библиотека · Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2020

ATP1A3-related epilepsy: Report of seven cases and literature-based analysis of treatment response.

Gasser Marius, Boonsimma Ponghatai, Netbaramee Wiracha, Wechapinan Thanin, Srichomthomg Chalurmpon, Ittiwut Chupong, Krenn Martin, Zimprich Fritz, Milenkovic Ivan, Abicht Angela, Biskup Saskia, Roser Timo, Shotelersuk Vorasuk, Tacke Moritz, Kuersten Marianne, Wagner Matias, Borggraefe Ingo, Suphapeetiporn Kanya, von Stülpnagel Celina

СтатьяПеревод в очереди

Аннотация

ATP1A3 related disease is a clinically heterogeneous condition currently classified as alternating hemiplegia of childhood, rapid-onset dystonia-parkinsonism and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss. Recently, it has become apparent that a remarkably large subgroup is suffering from often difficult-to-treat epilepsy. The aim of the present study was to assess the prevalence and efficacy of commonly used anti-epileptic-drugs (AEDs) in patients with ATP1A3 related seizures. Therefore, we performed a retrospective study of patients in combination with a systematic literature-based review. Inclusion criteria were: verified ATP1A3 mutation, seizures and information about AED treatment. The literature review yielded records for 188 epileptic ATP1A3 patients. For 14/188 cases, information about anti-epileptic treatment was available. Combined with seven unpublished records of ATP1A3 patients, a sample size of 21 patients was reached. Most used AED were levetiracetam (n = 9), phenobarbital (n = 8), valproic acid (n = 7), and topiramate (n = 5). Seizure reduction was reported for 57% of patients (n = 12). No individual AEDs used (either alone or combined) had a success rate over 50%. There was no significant difference in the response rate between various AEDs. Ketogenic diet was effective in 2/4 patients. 43% of patients (n = 9) did not show any seizure relief. Even though Epilepsy is a significant clinical issue in ATP1A3 patients, only a minority of publications provide any information about patients' anti-epileptic treatment. The findings of treatment effectiveness in only 57% (or lower) of patients, and the non-existence of a clear first-line AED in ATP1A3 related epilepsy stresses the need for further research.

Для цитирования: Gasser Marius, Boonsimma Ponghatai, Netbaramee Wiracha, Wechapinan Thanin, Srichomthomg Chalurmpon, Ittiwut Chupong, Krenn Martin, Zimprich Fritz, Milenkovic Ivan, Abicht Angela, Biskup Saskia, Roser Timo, Shotelersuk Vorasuk, Tacke Moritz, Kuersten Marianne, Wagner Matias, Borggraefe Ingo, Suphapeetiporn Kanya, von Stülpnagel Celina. ATP1A3-related epilepsy: Report of seven cases and literature-based analysis of treatment response.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2020. DOI: 10.1016/j.jocn.2020.01.041.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.